| Project/Area Number |
16K21639
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
Biological pharmacy
|
|---|
| Research Institution | Chiba Cancer Center (Research Institute) |
|---|
Principal Investigator |
Morinaga Takao 千葉県がんセンター(研究所), がん治療開発グループ, 研究員 (30757000)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 悪性中皮腫 / 遺伝子治療 / アデノウイルス / チロシンキナーゼ / 細胞周期 / adenovirus / wee1 / apoptosis / replication / cell cycle / p53 / Wee1 キナーゼ / 細胞障害活性 / アポトーシス / 癌 / ウイルス / シグナル伝達 |
|---|
| Outline of Final Research Achievements |
Malignant mesothelioma is an intractable disease; thereby, development of innovative new drugs, which has a non-traditional strategy for cancer treatment is required. We focused on effectiveness of oncolytic adenoviruses on mesothelioma and further explored a drug that can strengthen the antitumor effect of the viruses. Our results suggested that a Wee1 kinase inhibitor could enhance the replication of adenoviruses and augment the cytotoxicity induced by the viruses through the apoptotic pathway.
|
